Meeting
2022 ASCO Annual Meeting
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
Authors
Lifen Cao
University Hospitals at Cleveland Medical Center, Cleveland, OH
Lifen Cao , Christopher W. Towe , Nickolas Stabellini , Amanda L. Amin , Alberto J. Montero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 543)
DOI
10.1200/JCO.2022.40.16_suppl.543
Abstract #
543
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.
First Author: Vladislav Berdunov
Poster
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
First Author: Nicholas Siu-Li
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden